adenomyosis

Published online: 2020-10-20
108
Pathology and Pathogenesis of Adenomyosis
Maria Facadio Antero, MD1
Ayse Ayhan, MD, PhD2
1 Department of Gynecology and Obstetrics, Johns Hopkins University
School of Medicine, Baltimore, Maryland
2 Department of Pathology, Johns Hopkins University School of
Medicine, Baltimore, Maryland
James Segars, MD1
Ie-Ming Shih, MD, PhD1,2
Address for correspondence Ie-Ming Shih, MD, PhD, Department of
Gynecology and Obstetrics, Johns Hopkins Medical Institutions, 1550
Orleans Street, CRB2, RM305, Baltimore, MD (e-mail: [email protected]).
Abstract
Keywords
►
►
►
►
adenomyosis
endometriosis
pathology
pathogenesis
Adenomyosis represents a unique pathophysiological condition in which normalappearing endometrial mucosa resides within myometrium and is thus protected
from menstrual shedding. The resulting ectopic presence of endometrial tissue
composed of glands and stroma is thought to affect normal contractile function
and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and
adverse obstetric outcomes. Since the first description of adenomyosis more than
150 years ago, pathologists have studied this lesion by examining tissue specimens,
and have proposed multiple explanations to account for its pathogenesis. However, as
compared with endometriosis, progress of adenomyosis research has been, at best,
incremental mainly due to the lack of standardized protocols in sampling tissue and a
lack of consensus diagnostic criteria in pathology practice. Despite these limitations,
recent advances in revealing the detailed anatomy and biology of eutopic endometrium offer an unprecedented opportunity to study this common but relatively understudied disorder. Here, we briefly summarize the pathological aspects of adenomyosis
from an historical background, and discuss conventional morphology and recent
tissue-based molecular studies with a special emphasis on elucidating its tissue of
origin from a pathologist’s perspective. We also discuss unmet needs in pathology
studies that would be important for advancing adenomyosis research.
Maintaining tissue specification and cohesiveness are cardinal features in multicellular organisms, and this evolutionendowed tenet requires that adult tissues of the same type
stay together. Breaking this rule has serious consequences for
the organism as exemplified by tumor invasion and metastasis. An exception applies to two related benign and common gynecologic disorders, adenomyosis and endometriosis,
in which normal-appearing endometrium resides in myometrium and in peritoneal tissue, respectively (►Fig. 1).1
Thus, the pathologies of adenomyosis and endometriosis are
unique among human nonmalignant diseases. Because of
their anatomic locations and the unique microenvironments,
the ectopic endometrial tissues may or may not observe the
ovarian hormonal cycles and can have molecular changes
that are distinct from eutopic endometrium despite their
similar morphological appearance.
Issue Theme Adenomyosis and
Endometriosis; Guest Editors, Linda C.
Giudice, MD, PhD, MSc, Lisa M.
Halvorson, MD, Elizabeth A. Stewart, MD,
and Luk Rombauts, PhD, FRANZCOG, MD
Adenomyosis is a major gynecologic disorder causing chronic
pelvic pain, dysmenorrhea, dyspareunia, infertility, and adverse
obstetric outcomes.2,3 It has been estimated that adenomyosis
affects 10 to 80% of premenopausal women, and its prevalence is
even higher in women with infertility and chronic pelvic pain.4,5
Like endometriosis, adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work
productivity, without mentioning the compromised quality of
life.6,7 Here, we provide a succinct summary of our current
understanding of adenomyosis from a pathology perspective.
We discuss how the term “adenomyosis” has evolved from a
historical background, the histopathological features, the challenge in its classification, and current concepts pertaining to
development of adenomyosis. We also propose critical tasks
that are fundamentally important for accelerating progress,
both biological and translational, in adenomyosis research.
Copyright © 2020 by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA.
Tel: +1(212) 760-0888.
DOI https://doi.org/
10.1055/s-0040-1718922.
ISSN 1526-8004.
Downloaded by: World Health Organization ( WHO). Copyrighted material.
Semin Reprod Med 2020;38:108–118
Antero et al.
Fig. 1 The ectopic endometrium and eutopic endometrium. The diseases related to ectopic endometrium include adenomyosis, deep
infiltrating endometriosis, peritoneal endometriosis, and ovarian endometriotic cyst (endometrioma). The insets illustrate the similar histology
of eutopic endometrium (top) and ectopic lesions (bottom), containing both glandular epithelium and stroma. (Modified from Wang et al1; [©
IM Shih, Johns Hopkins University].)
A Historical Perspective
First, let us wind back the clock to 1860 when Karl von
Rokitansky initially described endometrial glands embedded
in the uterine myometrium.8 He named this condition
“cystosarcoma adenoids uterinum,” reflecting the essence
of adenomyosis—glandular and sometimes cystic structures
forming tumor-like lesions in uteri. Chiari9 also observed a
similar lesion which he called “salpingitis isthmica nodosa
(SIN)” around the fallopian tube musculature and believed
that it was a variant of adenomyosis. Subsequently, other
investigators in the late 19th century attempted to explain
the possible mechanisms for the establishment of adenomyosis. Meyer10 was the first to propose the theory of
“epithelial heterotopy,” an analogy to wound healing, where
epithelial cells would invade inflammatory tissue that was
damaged. He developed this theory after finding endometrial
glands in the suture lines of a patient who had undergone a
prior uterine ventrofixation secondary to pelvic pain. He
thought that these glands were derived from either embryonic or “well-differentiated” cells.
Cullen, who established gynecologic pathology as a subspecialty of pathology at the Johns Hopkins Hospital, pioneered a systematic and comprehensive description of what
we know today as adenomyosis. He suggested a mechanism in
which endometrial glands and stroma in endometrium could
invade the underlying myometrium, as, in some cases, a direct
connection between uterine cavity and the heterotopic glands
could be seen.11 Another important contribution by Cullen was
that he attributed the pathology of adenomyosis to clinical
phenotypes including lengthened menstrual periods and pelvic pain. He further proposed that hysterectomy was the
preferred treatment, as unlike a well-circumscribed leiomyoma it was often hard to dissect out adenomyomas because
their “growth was so interwoven with the normal muscle.”12
Cullen’s theory of mucosal invasion faced challenges for many
years, as other contemporary theories argued that displacement of mesonephric elements together with idiopathic stromal hyperplasia were responsible for adenomyosis.13,14 It was
not until the 1920s that the endometrial origin of adenomyosis
was widely accepted. This acceptance coincided with Sampson’s theory of retrograde menstruation to explain how menstruated endometrial tissue caused endometriosis,15 and
helped to clarify that adenomyosis and endometriosis were
two different disease entities, although both lesions were
thought to originate from uterine endometrium.
Finally, the term “adenomyosis uteri” was introduced in
1925 by Frankl,16 who described the mucosal invasion of the
myometrium. He explained that the term was chosen so that
it remained clear that the condition was not caused by an
inflammatory process as had been previously proposed. He
also further differentiated adenomyomas from adenomyosis,
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
109
Downloaded by: World Health Organization ( WHO). Copyrighted material.
Pathology and Pathogenesis of Adenomyosis
Pathology and Pathogenesis of Adenomyosis
Antero et al.
stating that the former originated independently within the
uterus, and the latter was diffuse with a direct connection
with the endometrium. It was only in 1972 that the current
histological definition of adenomyosis was put forth by Bird
et al17 positing that adenomyosis was characterized by the
“… benign invasion of endometrium into myometrium,
producing a diffusely enlarged uterus which microscopically
exhibits ectopic, nonneoplastic, endometrial glands and
stroma surrounded by hypertrophic and hyperplastic myometrium.” The modern histological definition was thus born.
Pathology of Adenomyosis and Correlation
with Imaging Results
Grossly, the uterus may appear slightly enlarged and globular
due to myometrial hypertrophy in severe cases of adenomyosis
(►Fig. 2a),18–20 but in general, the involved uteri preserve the
overall contour, and are rarely bigger than a 12-week size gravid
uterus.17,21,22 The cut surface of adenomyotic foci is characterized by hyperfasciculated and trabeculated areas of myometrium, which correspond with myometrial hypertrophy
(►Fig. 2b). On gross appearance, adenomyosis, unlike leiomyoma, does not manifest a well-demarcated border (►Fig. 2c,
d). The adenomyotic foci may appear grossly indistinct or as a
white-gray mass with areas of brown-staining secondary to
hemolyzed blood and hemosiderin deposits.23 Blood-filled
cysts can also be occasionally observed.24 In some cases, uterine
adenomyosis can form localized nodules that grossly mimic
leiomyomas. These focal adenomyotic nodules are known as
adenomyomas, and are composed of smooth muscle surrounding endometrial glands and stroma. Upon gross examination,
adenomyomas, unlike leiomyomas, are unencapsulated, and
the hypertrophied myometrium is often mixed with the surrounding normal myometrium (►Fig. 2c, d).
Microscopically, adenomyosis consists of irregularly
shaped islands of endometrial glands and stroma within
the myometrium. They are always multiple, and we believe
that the discrete islands, especially those are adjacent to each
other on cross tissue sections, are not separated but rather
are interconnected, which can be seen if a series of sequential
sections are examined or a three-dimensional reconstruction can be generated. Thus, the architecture of adenomyosis
is distinct from that of the functional endometrium, in which
the glands are solitary, nonbranching, and longitudinally
arranged (►Fig. 2e, f ). In fact, the glands and stroma of
adenomyotic foci architecturally resemble the basalis layer
in eutopic endometrium, where a complex horizontally
connected glandular structure is normally formed.25 The
gland-to-stroma ratio varies widely among adenomyoma
foci, and some may have attenuated or undetectable stromal
components,26 which may reflect sampling issue in which
the tangential cut surface does not contain the neighboring
stroma. The adenomyotic endometrium may retain its proliferative potential, which could contribute to endometrial
regrowth and failure after endometrial ablation.27 Glands
can vary in shape and size, with 5% of them forming cystic
structures filled with cellular debris and hemosiderin-laden
macrophages (►Fig. 2g).28 The stromal components of
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
Fig. 2 Gross and microscopic features of adenomyosis. (a) The involved
uterus appears slightly enlarged and globular. (b) A bivalved surface from a
hysterectomy specimen shows multiple foci of adenomyosis with petechialike areas (yellow arrows) in myometrium. The smooth muscle appears
hypertrophied and disarrayed. (c, d) Comparison of gross appearance of
adenomyosis (AD) and leiomyoma (LM). Formalin fixed cross-section in C
and hematoxylin and eosin (H&E) stained section in D. (e) Microscopic
features showing presence of glandular epithelium and stroma surrounded
by hypertrophic smooth muscle cells. (H&E stain 20 magnification). (f)
Higher magnification view to show the resemblance of epithelial and
stromal components of adenomyosis to eutopic endometrium (H&E stain
40 magnification). (g) Ectopic endometrial tissue showing foci of hemorrhage with histiocytes and hemosiderin-laden macrophages (red arrow)
(H&E stain 20 magnification). (h) Marked decidualization with small
inactive glands in adenomyosis seen after exogenous progestin therapy.
(H&E stain 20 magnification).
adenomyosis present a monotonous appearance, and are
usually inactive and nonmitotic. Secretory changes, including stromal decidualization, have been observed during
gestation and exogenous progestin therapy (►Fig. 2h).
Adenomyosis is never found in a leiomyoma.
In normal uteri, the junction between endometrium and
myometrium is not always well demarcated, and an irregular
border with focal extension of endometrial tissue into superficial myometrium is not uncommon. As such, tangential sections can reveal seemingly detached foci of glands and stroma
beneath endometrium, and these foci may be mistakenly
diagnosed as superficial adenomyosis, further confounding
Downloaded by: World Health Organization ( WHO). Copyrighted material.
110
clinicopathological studies of adenomyosis. Tissue biomarkers
that help distinguish true adenomyosis from endometrial
extensions from the irregular border would be useful. Along
this line, upregulation of the biomarker STING (stimulator of
interferon gene) has recently been reported to distinguish
epithelial cells of adenomyosis from eutopic endometrium.29
The endometrial–myometrial junctional zone located between the endometrium and the inner myometrium has
received much attention in adenomyosis research because
this zone is often thickened and exhibits architectural changes
that may lead to abnormal uterine peristalsis.30,31 Architectural changes include loss of nerve fibers and smooth muscle
hypertrophy.32 At the ultrastructural level, these myocytes
associated with adenomyosis show abnormal nuclear and
mitochondrial shapes, abundant myelin bodies and intermediate filament aggregates, extensive endoplasmic reticulum,
and increased expression of oxytocin receptors.33,34 Although
these findings and their biological significance requires validation, the morphological abnormalities in the junctional zone
in adenomyosis may play a role in hyperperistalsis. It is not
certain whether hyper- or dysperistalsis facilitates invasion of
endometrial glands into the myometrium,35 or whether the
presence of abundant ectopic endometrial tissues in myometrium interferes with or triggers peristalsis.
Adenomyotic lesions also have a higher angiogenic potential, as evidenced by an increased level of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α
(HIF-1α) compared with paired eutopic endometrium and
with endometrium from disease-free women.36 Furthermore, although verification will be required, it appears
that ectopic endometrium contains a greater density of
Antero et al.
microvessels than adjacent normal endometrium or eutopic
endometrium of disease-free women.37
The aforementioned pathologic features of adenomyosis
can explain many of the commonly observed findings
reported in ultrasound or MRI studies. Subendometrial
echogenic linear striations, nodules, and/or asymmetrical
myometrial bulkiness may be related to muscular hypertrophy in different regions in reaction to the presence of ectopic
endometrium. Moreover, hyperechoic islands and subendometrial cysts can be a result of focal cystic dilatation of the
fluid-filled glands in adenomyosis. Thus, the irregular endometrial–myometrial junction may reflect the complex and
convoluted connection between endometrium and the underlying adenomyosis. In color Doppler sonography, a general increase in vascularity and in numbers of tortuous
vessels penetrating myometrium is likely associated with
enhanced angiogenesis. Thickening of the junctional zone,
visualized as a hypoechoic halo beneath the endometrial
layer (usually greater than 12 mm), is suggestive of an
adenomyosis. However, it is challenging to correlate such
thickening with adenomyosis-associated histopathological
findings.
Unusual Pathology and Related Gynecologic
Conditions
Hyperplastic changes with or without atypia are not
unusual in adenomyosis, and can often be detected in
the corresponding eutopic endometrium. However, malignant transformation of adenomyosis is a rare event occurring mostly in postmenopausal women (►Fig. 3).38,39
Fig. 3 Atypical hyperplasia and low-grade endometrioid carcinoma arising from adenomyosis. (a) Foci of atypical hyperplasia within a
preexisting adenomyosis lesion. (b) An incipient low-grade endometrioid carcinoma arising from adenomyosis with cancerous tissue coexisting
with ectopic benign glandular tissue (hematoxylin and eosin stain 20 magnification).
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
111
Downloaded by: World Health Organization ( WHO). Copyrighted material.
Pathology and Pathogenesis of Adenomyosis
Pathology and Pathogenesis of Adenomyosis
Antero et al.
Endometrioid carcinoma is the most common histological
type of malignant transformation of adenomyosis, but
serous carcinoma, clear cell carcinoma, and poorly differentiated carcinoma may also be seen.40 Pathologic findings
that suggest malignant transformation of adenomyosis
include the presence of cancerous tissue and ectopic endometrial tissue in the same lesion, diagnosis of adenomyosis,
transformation evidence between benign and malignant
gland structures, and exclusion of other sources of tumor
invasion or metastasis.41 In addition to epithelial cells,
stromal cells in adenomyosis can also undergo neoplastic
transformation to form intramural adenosarcoma, but this
is exceedingly rare.
Other unusual subtypes of adenomyosis have been
described. As mentioned earlier, adenomyomas are a nodular form of adenomyosis involving myometrium focally,
which distinguishes it from the diffuse appearance of
conventional adenomyosis. Both adenomyomas and diffuse
types of adenomyosis may be present in the same specimen. One lesion related to adenomyoma is “polypoid
adenomyoma” which is a benign tumor commonly arising
from the lower uterine segment forming either a single
polypoid lesion or multiple polyps.42 Histologically, endometrial glands are embedded in a fibromuscular or muscular stroma. The glands are usually lined with
endometrioid cells and embedded by smooth muscle fascicles.42,43 The endometrial stromal cells are not always
present, arguing that atypical polypoid adenomyoma is
related to conventional adenomyosis.
SIN, once considered to be a variant of adenomyosis, is
now mostly seen as an acquired fallopian tube lesion
analogous to adenomyosis of the uterus. Grossly, SIN
appears as a nodular protrusion on the tubal serosa and
is most often localized to the isthmic portion of the tube.
SIN can cause either infertility due to luminal obstruction or
tubal pregnancy due to the irregular and convoluted lumen
of the fallopian tubes. Adenomyosis and SIN may share
pathogenic mechanisms, as they have similar glandular
proliferation with an associated muscular hypertrophy
phenotype.
Pathology-Based Classification
Several classification systems based on histological features
of adenomyosis have been proposed: (1) depth of myometrium involvement, (2) location of adenomyotic lesions, and
(3) whether the myometrial involvement is diffuse or localized. However, a standard and well-accepted system for
histological classification has not yet been established, in
part because studies attempting to correlate pathological
features with clinical presentations have not shown significant or reproducible results. We believe that this is related to
how specimens are processed and examined. For example,
there is a direct correlation between the number of histologic
sections examined and the prevalence of adenomyosis. In a
study by Bird et al,17 the prevalence of adenomyosis increased from 31 to 61.5% when additional histologic uterine
sections were obtained and examined. Despite this fact,
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
there is no consensus among pathologists regarding sampling hysterectomy specimens. Moreover, not all adenomyotic lesions are created equal. It is plausible that other than
conventional histopathology, adenomyosis can be classified
according to developmental patterns or the molecular alterations. Molecular classification would be welcome but appear to be out of reach until we better understand the
pathogenesis of adenomyosis, and can correlate molecular
changes and clinical phenotypes.
Nevertheless, it is worth briefly reviewing classifications
that have been proposed in the past so that investigators can
design better studies for future classification of adenomyosis. Since the depth of myometrial involvement is the most
obvious histopathological feature of adenomyosis, many
investigators have proposed classification systems based
on the depth of glands within the myometrium. This is
analogous to endometrial carcinoma in which the depth of
myometrial invasion by the cancer cells determines the FIGO
stage, which is highly associated with clinical outcome.44,45
For example, one study46 proposed that superficial adenomyosis could be characterized as glands within 40% of the
myometrial thickness, intermediate adenomyosis when
glands were present in 40 to 80% of myometrial thickness,
and deep adenomyosis when glands were seen beyond 80%
of the myometrial thickness. Another study applied onethird and two-third as the cut-off.47 Unfortunately, those
proposed cut-offs are arbitrary, lacking biological or clinical
grounds.
In general, significant conflicts are seen among results of
studies aimed at correlating disease symptoms with depth
of glands within the myometrium. In some studies, the two
most common symptoms of pain (dysmenorrhea, chronic
pelvic pain, or dyspareunia) and abnormal uterine bleeding
(AUB, or menorrhagia) were assessed.23 Some studies found
a positive correlation between depth of adenomyosis involvement and dysmenorrhea,17,46,48 whereas others found
no correlation at all.49 Dysmenorrhea has been reported to
correlate with the number of glandular tissue foci seen
within the myometrium.46,48,49 Dyspareunia is also associated with the number of lesion foci but not with depth of
the lesion.49 Diffuse adenomyosis has been associated with
worse dysmenorrhea than focal disease, while the later has
been associated with infertility especially when located in
the outer myometrium.50,51 Conflicting data have been
reported concerning the relationship of AUB and histologic
features such as depth and glandular density. Most studies
have shown that there is no relationship between AUB and
glandular depth, but the numbers of adenomyotic foci per
slide show a strong correlation with the reported bleeding
volume. In one report, menorrhagia was found to be more
prevalent in women with deep adenomyosis than in those
with intermediate disease.46 Another study used the gross
appearance of uterus and tissue consistency at the time of
surgery was used to classify adenomyosis as either diffuse
type or as sclerotic type in which densely packed collagen
fibers surrounded the adenomyotic foci.28 Menorrhagia was
found to be more frequently present in the diffuse type than
in other types.
Downloaded by: World Health Organization ( WHO). Copyrighted material.
112
Pathogenesis of Adenomyosis
The pathogenesis of adenomyosis, especially the steps through
which normal-appearing endometrial tissue is displaced to
myometrium, and the mechanisms by which adenomyotic foci
cause symptoms, remain largely unclear. Current evidence
from histopathological observations and recent molecular
genetic studies indicates that adenomyosis is derived from
invagination from the basal layer of endometrium into adjacent myometrium, a modern view resonant with what Cullen
proposed almost one century ago. Tissue sections of adenomyotic lesions that are prepared for pathology diagnosis almost
always show multiple irregularly shaped seemingly interconnected endometrial glands embedded in stroma. This is one of
the salient morphological features of adenomyosis, and suggests that the glands within adenomyosis are highly convoluted, forming a labyrinth network, and do not display a simple
arrangement (►Fig. 4a). This architecture of adenomyosis
resembles that in the basal layer of endometrium.
Comparison of eutopic endometrium between uteri with and
without adenomyosis may offer some clues. In hysterectomy
specimens showing adenomyosis, it is not uncommon to observe a more irregular endo-myometrial border with endometrial glands and stroma “attempting” to extend from basalis into
Antero et al.
superficial myometrium (►Fig. 4b). Several studies argue that
this involves a true invasion process. If this is the case, it would be
different from that seen in carcinoma. If this were a bone fide
invasion, both glandular epithelium and stroma would have to
acquire a constellation of complex molecular and cellular
changes including expression of proteases that degrade the
extracellular matrix, enhanced motility, and the ability to
comigrate and dissect into remarkably cohesive smooth muscle
layers. These features are highly unusual for any adult normalappearing tissues. Moreover, adenomyosis does not exhibit a
classical stromal reaction (desmoplasia), which is one of the
hallmarks of tumor invasion under microscopic examination.
Rather, we propose that the genesis of adenomyosis derives
from an embryonic or an early postnatal invagination of the
basal endometrium followed by extension deep into myometrium, likely associated with a physiological or pathological
defect of the endometrial–myometrial junction. This is supported by reported cases of fetal and prepubescent adenomyosis
and endometriosis.52–54 It is also possible that the basal endometrium can acquire access to myometrium in a gestational
uterus where the myometrium is relatively loosened due to
interstitial edema and focal disarray of the muscular layer.
Nevertheless, the eutopic endometrium of adenomyosis
patients may possess certain characteristics that differ from
Fig. 4 Adenomyosis originating from the basal layer of endometrium. (a) A schematic representation of the development of adenomyosis with
the focal extension of a single clonally distinct endometrial gland from the endometrial basalis into the myometrium. In the myometrium, the
incipient adenomyosis continues to clonally expand to form intricate and interconnected glandular foci which are similar to the endometrial
basalis layer. Together with the “invading” gland, stromal cells also migrate and clonally expand. Different color lines (glands) and dots (stroma)
represent clonally distinct subpopulations. (b) Immunostaining of cytokeratin suggesting the process of early adenomyosis development. The
adenomyotic tissue appears to descend from the basal endometrium through the endometrial myometrial interface (dashed red line) with the
vertical “invasion” of ectopic glandular and stromal tissue into myometrium. (20 magnification).
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
113
Downloaded by: World Health Organization ( WHO). Copyrighted material.
Pathology and Pathogenesis of Adenomyosis
Pathology and Pathogenesis of Adenomyosis
Antero et al.
tissue of disease-free controls. Indeed, eutopic endometrium
in adenomyosis shows molecular changes which favor a
phenotype including increased angiogenesis and proliferation, decreased apoptosis, impaired immune function, and
altered hormone levels (increased estrogen production and
progesterone resistance).36,55–63 As a result, the basal layer
of eutopic endometrium has a propensity to migrate into
myometrium. If more comprehensive molecular studies are
able to confirm these findings, it may help explain the origins
and pathogenesis of adenomyosis.
Despite the histopathological evidence, the tissue origin
of adenomyosis from eutopic endometrium has only recently
received molecular validation; the identification of somatic
mutations using next-generation sequencing has provided
unequivocal evidence that adenomyosis develops from
eutopic endometrium.64 In many cases, the same somatic
mutations, including mutations in KRAS, could be detected in
both adenomyosis and corresponding eutopic endometrium,
suggesting that both ectopic and eutopic endometrium are
clonally related. In further separating glandular epithelium
from stroma of adenomyotic lesions using laser capture
microdissection, mutations were found to occur only in
the epithelial component of adenomyosis,64 a result similar
to a previous report showing that mutations in endometriosis are detected only in epithelium and not in stroma.65
Since adenomyosis may select cancer driver mutations
like KRAS, which is known to promote cell survival and
growth, thus confounding the clonality studies, we analyzed
selection-neutral mutations (synonymous and passenger
gene mutations) that do not confer any selection advantage
to cells in adenomyosis and matched basal layer samples of
eutopic endometrium. We found truncal mutations shared
by ectopic and eutopic endometrium, confirming that both
adenomyosis and associated eutopic endometrium are progeny of the same endometrial epithelial progenitor cells
(Lihong Li, MD; unpublished data October 1, 2020). However,
the adenomyosis and eutopic endometrium also harbor
distinct mutations. It is thus possible that after leaving the
endometrium, these progenitor cells develop into adenomyosis in myometrium through the acquisition of private
mutations.
An interesting result from this recent study is that the
KRAS mutations identified in adenomyosis were associated
with increased risk of cooccurring endometriosis, and that
KRAS mutations were often shared between the two coexisting pathologies.64 Whether this is coincidental or biologically meaningful is uncertain. Among different types of
endometriotic lesions, ovarian endometriotic cysts (69%)
were more likely to cooccur in KRAS-mutated adenomyotic
lesions than in deeply infiltrating endometriosis (46%), or
peritoneal endometriosis (11.6%). The study also showed
that KRAS mutations were often shared by cooccurring
adenomyosis and endometriotic lesions. This finding
appears consistent with other studies that have shown
that deeply infiltrating endometriosis and ovarian endometriomas harbor a variety of somatic cancer driver mutations
in PIK3CA, ARID1A, PPP2R1A, and/or KRAS.66,67 Since the
number of cases that have been subjected to mutational
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
analysis is limited, it remains to be confirmed if KRAS
mutations are important in the pathogenesis of adenomyosis
and endometriosis, or if the mutations merely represent
clonal markers without biological consequences.
Endometriosis is a common finding in patients with
adenomyosis and vice versa; both diseases cooccur in up
to 80% of patients.35,68–70 Among different types of endometriosis (►Fig. 1), deeply infiltrative endometriosis is more
commonly seen in women who have focal adenomyosis of
the outer myometrium.69 Like adenomyosis, deeply infiltrative endometriosis is characterized by the ectopic presence
of normal-appearing endometrial glands and stroma in the
smooth muscle layers of peritoneal organs such as urinary
bladder and bowel wall. Imaging studies have also shown an
increased incidence of deeply infiltrative endometriosis and
ovarian endometriomas in women with adenomyosis, specifically in adenomyosis involving the outer portion of the
myometrium.71–73 This suggests that adenomyosis and certain types of endometriosis may be biologically related.
Inoue et al. looked at the genetic landscape of the eutopic
endometrium in disease-free women and those with adenomyosis.64 As noted in other studies,74,75 the eutopic endometria of disease-free women were found to have somatic
cancer driving mutations in genes such as KRAS and PIK3CA
at much higher variant allele frequencies. Whether the single
cancer driver mutation, as occurs in ectopic endometrium, is
sufficient to drive the disease phenotypes remains to be
determined. It is still not known if these somatic mutations
are present at birth or acquired later in life, and whether
there is a genetic basis for the development of adenomyosis.
A recent study reports the mutational landscape of the
normal endometrium, showing that while age positively
correlates with the mutational burden in the endometrium,
some KRAS and PIK3CA mutations arise as early as the first
decade of life.75 The fact that adenomyosis develops later in
life, usually in the fourth or fifth decade, would seem to favor
the theory that the mutations are acquired, and that the
disease is not genetically predetermined. However, there
have been reports of adenomyosis developing in adolescents,24,76 and a case report of familial adenomyosis suggests
that the disease may have a genetic predisposition.77 Furthermore, relatively late diagnosis of adenomyosis as compared with endometriosis may be due to the diagnosis at
hysterectomy, which is uncommonly performed in young
women. Therefore, this interesting observation awaits confirmation in future studies.
Recently, differentially expressed genes were identified in
the eutopic endometrium of patients with adenomyosis.78
Using RNA sequencing followed by quantitative real-time
PCR and immunohistochemistry to validate findings, they
were able to identify 373 differentially expressed genes in
both ectopic and eutopic endometrium of adenomyosis
patients irrespective of menstrual cycle phases. Pathway
analysis of these differentially expressed genes identified
pathways responsible for regulating cellular proliferation
and growth, tissue morphology, and angiogenesis. Among
the identified differentially expressed genes was C/EBPβ, a
core node in the network analysis. The protein encoded by C/
Downloaded by: World Health Organization ( WHO). Copyrighted material.
114
Pathology and Pathogenesis of Adenomyosis
Conclusions
Adenomyosis is a benign gynecological disorder which consists of endometrial glands and stroma in the myometrium.
Although adenomyosis is related to endometriosis, both
lesions are thought to develop through different mechanisms. Results of recent molecular genetic studies imply
that adenomyosis is clonally derived from the basal endometrium, a result in resonance to the original Cullen’s
hypothesis that adenomyosis is the “invasion” of endometrial tissue into myometrium. Despite this fact, adenomyosis
develops its own progeny during development, and can be
molecularly distinguished from proximal eutopic endome-
115
trium. Several studies have also suggested that the eutopic
endometrium is inherently different in women with versus
without adenomyosis. However, the data on this are not
conclusive, and more rigorous research employing new
technologies with a larger case cohort will be needed to
validate these conclusions.
Future Directions
Despite new progress in our understanding of the pathology
and pathogenesis of adenomyosis, several fundamental
questions remain unanswered. Future pathology research
is needed to classify adenomyosis, and there is a pressing
need to understand the molecular and genetic underpinnings of this disease to facilitate new diagnostic and therapeutic paradigms.
Classification. Foremost is that a standardized classification system is developed in pathology to accurately document and report the disease and for a consistency in
designing basic and clinical studies for meaningful interpretation in future adenomyosis research. With the advent of
molecular technologies, we believe that a model integrating
clinical–pathological findings and molecular data such as
somatic mutation load, cancer driver mutation landscape,
and methylation profiles can be developed to correlate with
clinical phenotypes. This knowledge will be essential for a
better understanding of the pathogenesis of the disease.
Diagnosis. Development of practical diagnostic tools with
high accuracy is desirable to guide diagnosis and clinical
management. While MRI and ultrasound in the past two
decades have provided a noninvasive diagnostic tool for
adenomyosis, correlation of these with pathological findings
is warranting. As molecular signatures may likely differ in
eutopic endometrium of women with versus without adenomyosis, it is envisioned that adenomyosis could be reliably
predicted based on an endometrial molecular “adenomyosis
signature,” ideally including imaging results in a risk-predicting algorithm. Equally important is to develop blood-based
biomarkers that can help diagnose a woman with adenomyosis
with high sensitivity and specificity. This will be made possible
after a better understanding of the aberrant adenomyosisspecific secretome including exosome, miRNA species, and
unique protein biomarkers and their combinations.
Disease mechanisms. It is important for future directions
in studying the pathology of adenomyosis to focus on understanding molecular and genetic changes present in both
eutopic and ectopic lesions to determine their roles in the
development of adenomyosis and how they relate to specific
disease phenotypes. More studies are needed to determine
phylogenetic trajectories in the development of adenomyosis from eutopic endometrium. Future studies also need to
integrate the somatic mutation data to the theory of endometrial progenitor (stem cell-like) cells. While truncal mutations are shared by progenitor cells and their progeny,
indicating a clonal derivation of the latter from the former,
it remains unclear where those progenitor cells are physically located and how many they are in eutopic and ectopic
endometrium.
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
Downloaded by: World Health Organization ( WHO). Copyrighted material.
EBPβ acts as a transcription factor regulating expression of
genes that control cellular proliferation, differentiation, and
metabolism. C/EBPβ is also a key regulator of human endometrial stromal proliferation and differentiation.79,80 Other
pathways noted to be upregulated were IL-6, which has been
shown to be increased in adenomyotic stromal cells cocultured with macrophages,59 and ERK/MAPK, which has been
associated with uterine smooth muscle proliferation in
women with adenomyosis.81
The aforementioned evidence supports that invagination
of the endometrial basalis into the myometrium is the
favored model for the genesis of adenomyosis, as both
epithelial and stromal progenitor cells residing in basalis
are responsible not only for regenerating the entire functional layer after menstruation but can also promote adenomyosis development in the opposite direction. However, the
data should not be construed as supporting only this model
of the pathogenesis of adenomyosis. For example, it has also
been proposed that metaplasia of displaced embryonic pluripotent Müllerian remnants or differentiation of adult endometrial progenitor cells can also be the origin of
adenomyosis and its related lesion, endometriosis. Over
the last few years, it has been shown that stem cells present
in the endometrium basalis have the capacity to regenerate
and replace endometrium.82 This discovery has led to the
postulation that individual stem cells may disseminate locally or spread through the circulation to cause adenomyosis
if deposited in the myometrium and/or to cause endometriosis if deposited outside the uterus. Why are stem cells
present in the myometrium? A possible explanation is that
stem cells may be activated by tissue injury which favors
migration to the myometrium rather than the endometrium.83,84 However, this stem cell hypothesis faces a major
challenge, that is, how does an individual stem cell simultaneously could differentiate into both epithelium and stroma
which are present in all adenomyosis and endometriosis
lesions. If it does, both lesions should harbor the same
founder mutations, and future studies need to provide
such new evidence. From the standpoint of histopathology,
it is more likely that endometrial epithelial progenitor cells
reside in basal glands which may extend into the myometrium, where the progenitor cells and their glands accompanied by presumed stromal progenitor cells codevelop into
adenomyosis.
Antero et al.
Pathology and Pathogenesis of Adenomyosis
Antero et al.
Moreover, experimental designs of molecular studies
warrant revisiting. Historically bulk tissue analyses of the
lesions as a whole (combining epithelium and stroma) or
only on epithelium were conducted. Given the critical roles
of the stromal components in codeveloping adenomyosis
with glandular epithelium, it will be necessary to study
stroma alongside glandular epithelium by careful separation
of glands and stroma using laser-capture microdissection
before sequencing analysis and genome-wide profiling.
Finally, recent technological developments have greatly
helped advance our understanding of many human diseases,
especially in the fields of cancer and immunology. Tools such as
multiplexed imaging analysis, single cell profiling, and epigenetic and epigenomic methods all offer unprecedented opportunities to accelerate discovery of altered genetic and
molecular pathways in adenomyosis and associated eutopic
endometrium. The new knowledge will, in turn, inform clinical
studies for the development of improved diagnosis and treatments, which may be more patient centered, potentially
curative, and fertility sparing. This task is long overdue.
Funding
This study is supported by an NIH grant RO1HD096147
and by the Richard W. TeLinde Endowment, Department of
Gynecology and Obstetrics, Johns Hopkins University.
Conflict of Interest
None declared.
11 Kelly HA, Cullen TS. Myomata of the Uterus. Saunders; 1909
12 Cullen T. Adenomyoma of the Uterus. Philadelphia, PA: W. B.
Saunders Company; 1908
13 Von Recklinghausen F. Die Adenomyome und Cystadenome der
14
15
16
17
18
19
20
21
22
23
24
25
26
References
1 Wang Y, Nicholes K, Shih IM. The origin and pathogenesis of
endometriosis. Annu Rev Pathol 2020;15:71–95
27
2 Bruun MR, Arendt LH, Forman A, Ramlau-Hansen CH. Endome-
3
4
5
6
7
8
9
10
triosis and adenomyosis are associated with increased risk of
preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018;
97(09):1073–1090
Harada T, Taniguchi F, Amano HJapan Environment and Children’s
Study Group. , et al; . Adverse obstetrical outcomes for women with
endometriosis and adenomyosis: a large cohort of the Japan Environment and Children’s Study. PLoS One 2019;14(08):e0220256
Orazov M, Nosenko EN, Radzinsky VE, Khamoshina MB, Lebedeva
MG, Sounov MA. Proangiogenic features in chronic pelvic
pain caused by adenomyosis. Gynecol Endocrinol 2016;32
(Suppl 2):7–10
Seidman JD, Kjerulff KH. Pathologic findings from the Maryland
Women’s Health Study: practice patterns in the diagnosis of
adenomyosis. Int J Gynecol Pathol 1996;15(03):217–221
Nnoaham KE, Hummelshoj L, Webster PWorld Endometriosis
Research Foundation Global Study of Women’s Health Consortium. , et al; . Impact of endometriosis on quality of life and work
productivity: a multicenter study across ten countries. Fertil
Steril 2011;96(02):366–373.e8
Struble J, Reid S, Bedaiwy MA. Adenomyosis: a clinical review of a
challenging gynecologic condition. J Minim Invasive Gynecol
2016;23(02):164–185
Rokitansky C. Ueber Uterusdrusen-neubildung in Uterus and
Ovariul Sarcomen. Z Gesellschaft Aerzte Wien 1860;16:577
Chiari H. Zur pathologischen anatomie des eileitercatarrhs.
Z Heilkunde 1887;8:457–464
Meyer R. Uber eine adenomatose Wucherung der Serosa in einer
Bauchnarbe. Z Geburtshilfe Gynakol 1903;49:32–41
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
28
29
30
31
32
33
34
35
36
Uterus-und Tubenwandung: ihre Abkunft von Resten des Wolff’schen Körpers. Hirschwald1896
Diesterweg A. Ein Fall von Cystofibroma uteri verum. Z. Geburtshilfe 1883;9:191–195
Sampson JA. Peritoneal endometriosis due to the menstrual
dissemination of endometrial tissue into the peritoneal cavity.
Am J Obstet Gynecol 1927;14(04):422–469
Frankl O. Adenomyosis uteri. Am J Obstet Gynecol 1925;10(05):
680–684
Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of
the uterus. Am J Obstet Gynaecol 1972;112:583–593
Shutter J. Uterus-like ovarian mass presenting near menarche. Int
J Gynecol Pathol 2005;24(04):382–384
Bell CD, Ostrezega E. The significance of secretory features and
coincident hyperplastic changes in endometrial biopsy specimens. Hum Pathol 1987;18(08):830–838
Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998;4(04):312–322
Molitor JJ. Adenomyosis: a clinical and pathological appraisal. Am
J Obstet Gynecol 1971;110(02):275–284
Langlois PL. The size of the normal uterus. J Reprod Med 1970;4
(06):220–228
Azziz R. Adenomyosis: current perspectives. Obstet Gynecol Clin
North Am 1989;16(01):221–235
Brosens I, Gordts S, Habiba M, Benagiano G. Uterine cystic
adenomyosis: a disease of younger women. J Pediatr Adolesc
Gynecol 2015;28(06):420–426
Tempest N, Jansen M, Baker AM, et al. Histological 3D reconstruction and in vivo lineage tracing of the human endometrium.
J Pathol 2020;251(04):440–451
Goldblum JR, Clement PB, Hart WR. Adenomyosis with sparse
glands. A potential mimic of low-grade endometrial stromal
sarcoma. Am J Clin Pathol 1995;103(02):218–223
Haber G, Ferenczy A. Electrosurgical solutions to gynecological
problems. Contemp Obstet Gynecol 1993;1:25–36
Pistofidis G, Makrakis E, Koukoura O, Bardis N, Balinakos P, Anaf V.
Distinct types of uterine adenomyosis based on laparoscopic and
histopathologic criteria. Clin Exp Obstet Gynecol 2014;41(02):
113–118
Qu H, Li L, Wang TL, Seckin T, Segars J, Shih IM. Epithelial cells in
endometriosis and adenomyosis upregulate STING expression.
Reprod Sci 2020;27(06):1276–1284
Birnholz JC. Ultrasonic visualization of endometrial movements.
Fertil Steril 1984;41(01):157–158
Exacoustos C, Brienza L, Di Giovanni A, et al. Adenomyosis: threedimensional sonographic findings of the junctional zone and
correlation with histology. Ultrasound Obstet Gynecol 2011;37
(04):471–479
Quinn M. Uterine innervation in adenomyosis. J Obstet Gynaecol
2007;27(03):287–291
Mehasseb MK, Bell SC, Pringle JH, Habiba MA. Uterine adenomyosis
is associated with ultrastructural features of altered contractility in
the inner myometrium. Fertil Steril 2010;93(07):2130–2136
Guo S-W, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are
associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic
adenomyosis. Fertil Steril 2013;99(01):231–240
Leyendecker G, Bilgicyildirim A, Inacker M, et al. Adenomyosis
and endometriosis. Re-visiting their association and further
insights into the mechanisms of auto-traumatisation. An MRI
study. Arch Gynecol Obstet 2015;291(04):917–932
Goteri G, Lucarini G, Montik N, et al. Expression of vascular
endothelial growth factor (VEGF), hypoxia inducible factor-1α
(HIF-1α), and microvessel density in endometrial tissue in
Downloaded by: World Health Organization ( WHO). Copyrighted material.
116
Pathology and Pathogenesis of Adenomyosis
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
117
59 Yang JH, Wu MY, Chang DY, Chang CH, Yang YS, Ho HN. Increased
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
interleukin-6 messenger RNA expression in macrophage-cocultured endometrial stromal cells in adenomyosis. Am J Reprod
Immunol 2006;55(03):181–187
Yang J-H, Chen MJ, Chen HF, Lee TH, Ho HN, Yang YS. Decreased
expression of killer cell inhibitory receptors on natural killer cells
in eutopic endometrium in women with adenomyosis. Hum
Reprod 2004;19(09):1974–1978
Sotnikova N, Antsiferova I, Malyshkina A. Cytokine network of
eutopic and ectopic endometrium in women with adenomyosis.
Am J Reprod Immunol 2002;47(04):251–255
Mehasseb MK, Panchal R, Taylor AH, Brown L, Bell SC, Habiba M.
Estrogen and progesterone receptor isoform distribution through
the menstrual cycle in uteri with and without adenomyosis. Fertil
Steril 2011;95(07):2228–2235, 2235.e1
Nie J, Lu Y, Liu X, Guo SW. Immunoreactivity of progesterone
receptor isoform B, nuclear factor kappaB, and IkappaBalpha in
adenomyosis. Fertil Steril 2009;92(03):886–889
Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an
oligoclonal disorder associated with KRAS mutations. Nat Commun 2019;10(01):5785
Noë M, Ayhan A, Wang TL, Shih IM. Independent development of
endometrial epithelium and stroma within the same endometriosis. J Pathol 2018;245(03):265–269
Suda K, Nakaoka H, Yoshihara K, et al. Clonal expansion and
diversification of cancer-associated mutations in endometriosis
and normal endometrium. Cell Rep 2018;24(07):1777–1789
Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-associated
mutations in endometriosis without cancer. N Engl J Med 2017;
376(19):1835–1848
Di Donato N, Montanari G, Benfenati A, et al. Prevalence of
adenomyosis in women undergoing surgery for endometriosis.
Eur J Obstet Gynecol Reprod Biol 2014;181:289–293
Chapron C, Tosti C, Marcellin L, et al. Relationship between the
magnetic resonance imaging appearance of adenomyosis and
endometriosis phenotypes. Hum Reprod 2017;32(07):1393–
1401
Eisenberg VH, Arbib N, Schiff E, Goldenberg M, Seidman DS,
Soriano D. Sonographic signs of adenomyosis are prevalent in
women undergoing surgery for endometriosis and may suggest a
higher risk of infertility. Biomed Res Int 2017:8967803
Donnez J, Dolmans M-M, Fellah L. What if deep endometriotic
nodules and uterine adenomyosis were actually two forms of the
same disease? Fertil Steril 2019;111(03):454–456
Khan KN, Fujishita A, Koshiba A, et al. Biological differences
between intrinsic and extrinsic adenomyosis with coexisting
deep infiltrating endometriosis. Reprod Biomed Online 2019;39
(02):343–353
Dior UP, Nisbet D, Fung JN, et al. The association of sonographic
evidence of adenomyosis with severe endometriosis and gene
expression in eutopic endometrium. J Minim Invasive Gynecol
2019;26(05):941–948
Suda K, Nakaoka H, Yoshihara K, et al. Different mutation profiles
between epithelium and stroma in endometriosis and normal
endometrium. Hum Reprod 2019;34(10):1899–1905
Moore L, Leongamornlert D, Coorens THH, et al. The mutational
landscape of normal human endometrial epithelium. Nature
2020;580(7805):640–646
Zannoni L, Del Forno S, Raimondo D, et al. Adenomyosis and
endometriosis in adolescents and young women with pelvic pain:
prevalence and risk factors. Minerva Pediatr 2020
Arnold LL, Ascher SM, Simon JA. Familial adenomyosis: a case
report. Fertil Steril 1994;61(06):1165–1167
Xiang Y, Sun Y, Yang B, et al. Transcriptome sequencing of
adenomyosis eutopic endometrium: A new insight into its pathophysiology. J Cell Mol Med 2019;23(12):8381–8391
Wang W, Taylor RN, Bagchi IC, Bagchi MK. Regulation of human
endometrial stromal proliferation and differentiation by C/EBPβ
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020
Downloaded by: World Health Organization ( WHO). Copyrighted material.
37
women with adenomyosis. Int J Gynecol Pathol 2009;28(02):
157–163
Schindl M, Birner P, Obermair A, Kiesel L, Wenzl R. Increased
microvessel density in adenomyosis uteri. Fertil Steril 2001;75
(01):131–135
Mori M, Furusawa A, Kino N, Uno M, Ozaki Y, Yasugi T. Rare case of
endometrioid adenocarcinoma arising from cystic adenomyosis. J
Obstet Gynaecol Res 2015;41(02):324–328
Kazandi M, Zeybek B, Terek MC, Zekioglu O, Ozdemir N, Oztekin K.
Grade 2 endometrioid adenocarcinoma arising from adenomyosis of
the uterus: report of a case. Eur J Gynaecol Oncol 2010;31(06):719–721
Baba A, Yamazoe S, Dogru M, Ogawa M, Takamatsu K, Miyauchi J.
Clear cell adenocarcinoma arising from adenomyotic cyst: a case
report and literature review. J Obstet Gynaecol Res 2016;42(02):
217–223
Koike N, Tsunemi T, Uekuri C, et al. Pathogenesis and malignant
transformation of adenomyosis (review). Oncol Rep 2013;29(03):
861–867
Longacre TA, Chung MH, Rouse RV, Hendrickson MR. Atypical
polypoid adenomyofibromas (atypical polypoid adenomyomas)
of the uterus. A clinicopathologic study of 55 cases. Am J Surg
Pathol 1996;20(01):1–20
Young RH, Treger T, Scully RE. Atypical polypoid adenomyoma of the
uterus. A report of 27 cases. Am J Clin Pathol 1986;86(02):139–145
Singh N, Hirschowitz L, Zaino R, et al. Pathologic prognostic
factors in endometrial carcinoma (other than tumor type and
grade). Int J Gynecol Pathol 2019;38(Suppl 1):S93–s113
FIGO Committee on Gynecologic Oncology. FIGO staging for
carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol
Obstet 2014;125(02):97–98
Levgur M, Abadi MA, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol 2000;95(05):
688–691
Hulka CA, Hall DA, McCarthy K, Simeone J. Sonographic findings
in patients with adenomyosis: can sonography assist in predicting extent of disease? AJR Am J Roentgenol 2002;179(02):
379–383
Nishida M. Relationship between the onset of dysmenorrhea and
histologic findings in adenomyosis. Am J Obstet Gynecol 1991;
165(01):229–231
Sammour A, Pirwany I, Usubutun A, Arseneau J, Tulandi T.
Correlations between extent and spread of adenomyosis and
clinical symptoms. Gynecol Obstet Invest 2002;54(04):213–216
Grimbizis GF, Mikos T, Tarlatzis B. Uterus-sparing operative
treatment for adenomyosis. Fertil Steril 2014;101(02):472–487
Exacoustos C, Morosetti G, Conway F, et al. New sonographic
classification of adenomyosis: Do type and degree of adenomyosis correlate to severity of symptoms? J Minim Invasive Gynecol
2020;27(06):1308–1315
Signorile PG, Baldi F, Bussani R, et al. Embryologic origin of
endometriosis: analysis of 101 human female fetuses. J Cell
Physiol 2012;227(04):1653–1656
Signorile PG, Baldi A. Endometriosis: new concepts in the pathogenesis. Int J Biochem Cell Biol 2010;42(06):778–780
Benagiano G, Brosens I, Habiba M. Adenomyosis: a life-cycle
approach. Reprod Biomed Online 2015;30(03):220–232
Yang J-H, Wu MY, Chen CD, Chen MJ, Yang YS, Ho HN. Altered
apoptosis and proliferation in endometrial stromal cells of women with adenomyosis. Hum Reprod 2007;22(04):945–952
Jones RK, Searle RF, Bulmer JN. Apoptosis and bcl-2 expression in
normal human endometrium, endometriosis and adenomyosis.
Hum Reprod 1998;13(12):3496–3502
Wang F, Li H, Yang Z, Du X, Cui M, Wen Z. Expression of
interleukin-10 in patients with adenomyosis. Fertil Steril 2009;
91(05):1681–1685
Wang F, Wen Z, Li H, Yang Z, Zhao X, Yao X. Human leukocyte
antigen-G is expressed by the eutopic and ectopic endometrium
of adenomyosis. Fertil Steril 2008;90(05):1599–1604
Antero et al.
Pathology and Pathogenesis of Adenomyosis
Antero et al.
involves cyclin E-cdk2 and STAT3. Mol Endocrinol 2012;26(12):
2016–2030
80 Zahnow CA. CCAAT/enhancer-binding protein β: its role in breast
cancer and associations with receptor tyrosine kinases. Expert
Rev Mol Med 2009;11:e12
81 Streuli I, Santulli P, Chouzenoux S, Chapron C, Batteux F. Activation of the MAPK/ERK cell-signaling pathway in uterine smooth
muscle cells of women with adenomyosis. Reprod Sci 2015;22
(12):1549–1560
82 Hufnagel D, Li F, Cosar E, Krikun G, Taylor HS. The role of stem cells
in the etiology and pathophysiology of endometriosis. Semi
Reprod Med 2015;33(05):333–340
83 Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed
Online 2017;35(05):592–601
84 Gargett CE. Uterine stem cells: What is the evidence? Hum Reprod
Update 2007;13(01):87–101
Downloaded by: World Health Organization ( WHO). Copyrighted material.
118
Seminars in Reproductive Medicine
Vol. 38
No. 2-3/2020